GASTRIC CANCER TESTING, TREATMENT AND PREVENTION: TECHNOLOGIES AND GLOBAL MARKETS HLC174A October 2015 Usha Nagavarapu Project Analyst ISBN: 1-62296-167-6 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within the USA), or (+1) 781-489-7301 www.bccresearch.com information@bccresearch.com
TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 2 STUDY GOALS AND OBJECTIVES 2 REASONS FOR DOING THE STUDY 2 SCOPE AND FORMAT 2 INTENDED AUDIENCE 3 METHODOLOGY 3 RELATED BCC RESEARCH REPORTS 3 ANALYST'S CREDENTIALS 3 BCC RESEARCH WEBSITE 4 DISCLAIMER 4 CHAPTER 2 SUMMARY 6 SUMMARY TABLE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND TREATMENT MARKET, THROUGH 2020 ($ SUMMARY FIGURE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND TREATMENT MARKET, 2014-2020 ($ 7 7 CHAPTER 3 CANCER 9 WHAT IS CANCER? 9 CAUSES OF CANCER GROWTH 10 CANCER TREATMENT STRATEGIES 11 COMMON TREATMENTS AND PROBLEMS 11 Surgery 11 Chemotherapy 12 Radiation Treatment 12 Hormone Therapy 13 Targeted Therapy 13 GASTRIC CANCER 15 CHAPTER 4 INTRODUCTION TO GASTRIC CANCER 17 TABLE 1 MAIN CATEGORIES OF CANCER 17 DIGESTIVE SYSTEM AND CANCER 18 ESOPHAGEAL CANCER 18 GASTRIC CANCER GLOBAL INCIDENCE 21 SUBTYPES AND CHARACTERISTICS 22 SMALL INTESTINE CANCER 23 STOMACH CANCER/GASTRIC CANCER OVERVIEW 26 TABLE 2 TYPES OF STOMACH CANCER 29 TABLE 3 THE STAGES OF ADENOCARCINOMA STOMACH CANCER 29 TABLE 4 TESTS AND PROCEDURES USED TO DIAGNOSE STOMACH CANCER 30 CAUSES 32 TABLE 5 RISK FACTORS 32 TABLE 6 CAUSES OF GASTRIC CANCER 33 SYMPTOMS 33 TABLE 7 SYMPTOMS 33 THERAPEUTIC OPTIONS 34
RELATED CANCERS AND OVERVIEW 35 KIDNEY CANCER 35 TARGETED THERAPIES FOR KIDNEY CANCER 39 TABLE 8 DRUGS APPROVED FOR KIDNEY (RENAL CELL) CANCER 40 SORAFENIB (NEXAVAR) 40 SUNITINIB (SUTENT) 40 TEMSIROLIMUS (TORISEL) 41 EVEROLIMUS (AFINITOR) 41 BEVACIZUMAB (AVASTIN) 41 PAZOPANIB (VOTRIENT) 41 AXITINIB (INLYTA) 42 LIVER 42 PANCREATIC CANCER 46 SUMMARY 51 CHAPTER 5 GASTRIC CANCER SCREENING, DIAGNOSIS AND MARKET 53 SCREENING 53 SCREENING METHODS 53 TABLE 9 GASTRIC SCREENING METHODS 54 SCREENING AND BENEFITS 55 SCREENING MODALITIES 55 Barium-Meal Gastric Photofluorography 55 Gastric Endoscopy 56 Serum Pepsinogen 56 GASTRIC SCREENING IN UNITED STATES 57 GASTRIC CANCER SCREENING WORLDWIDE 57 Conclusions 58 CHAPTER 6 GASTRIC SCREENING AND DIAGNOSIS MARKET 60 TABLE 10 ESTIMATED INCIDENCE, MORTALITY AND PREVALENCE OF STOMACH CANCER WORLDWIDE, 2012 (THOUSANDS) SCREENING 61 TABLE 11 GLOBAL GASTRIC CANCER DIAGNOSTIC AND SCREENING MARKET, THROUGH 2020 ($ DIAGNOSIS AND PROGNOSIS 64 TESTS 64 TABLE 12 TESTS AND PROCEDURES TO DETECT GASTRIC CANCER 64 IMAGING TESTS 65 Upper Gastrointestinal (GI) Series 66 Computed Tomography (CT or CAT) Scan 66 Magnetic Resonance Imaging (MRI) Scan 66 Positron Emission Tomography (PET) Scan 67 Chest X-Ray 67 Laparoscopy 67 Helicobacer Pylori 68 TABLE 13 TESTS USED TO DETECT H. PYLORI 68 Lab Tests 68 Costs 68 60 62
TABLE 14 GASTROINTESTINAL ENDOSCOPY EXAMINATIONS IN U.S., 2009 ( SERUM PEPSINOGEN PREDICTS GASTRIC ADENOCARCINOMA 70 68 CHAPTER 7 GASTRIC CANCER TREATMENT OPTIONS 72 CURRENT PRACTICES 72 TABLE 15 TYPES OF STANDARD TREATMENT 72 CHEMOPREVENTION 72 ANTIOXIDANTS 72 ANTIBIOTICS 73 Non-Steroidal Anti-Inflammatory Drugs (Including Aspirin) 73 STAGING 73 Sentinel Lymph Node Mapping 73 Surgery 74 Chemotherapy 74 Radiation Therapy 75 Chemoradiation 75 TARGETED THERAPY 75 Drugs Approved for Stomach (Gastric) Cancer 75 TABLE 16 APPROVED DRUGS FOR GASTRIC CANCER 76 PROGNOSIS 76 PREVENTION 76 CHEMOTHERAPY DRUGS AND COMBINATIONS 77 TARGETED THERAPY OVERVIEW 77 Pembrolizumab 78 Ramucirumab 79 Afinitor (Everolimus) 81 Apatinib 85 FAILED DRUGS 86 Cetuximab 86 Tykerb (Lapatinib) 86 Expected Treatment Outcomes 87 GASTROINTESTINAL CANCER: MONOCLONAL ANTIBODIES 87 TABLE 17 RECENT SURFACE ANTIGENS TARGETED BY MARKETED ANTIBODY THERAPEUTICS TABLE 18 MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER TREATMENT TABLE 19 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER, 2014 ($ FIGURE 1 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER, 2014 ($ TABLE 20 GASTRIC CANCER AND ANTIBODIES IN DEVELOPMENT 91 AVASTIN (BEVACIZUMAB) 91 HERCEPTIN (TRASTUZUMAB) 92 VECTIBIX (PANITUMUMAB) 94 88 88 89 89 CHAPTER 8 MARKET DYNAMICS AND OVERVIEW 96 TABLE 21 CANCER KEY FACTS 96
STANDARD TREATMENTS 97 GLOBAL CANCER MARKET TRENDS 97 TABLE 22 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030 (MILLIONS OF PATIENTS) FIGURE 2 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030 (MILLION PATIENTS) TABLE 23 GLOBAL CANCER RELATED ESTIMATED DEATHS BY REGION, 2012 AND 2030 ( FIGURE 3 GLOBAL CANCER RELATED ESTIMATED DEATHS, BY REGION 2012 AND 2030 ( TABLE 24 APPROVED ONCOLOGY DRUGS, 2013-2015 100 GLOBAL ONCOLOGY MARKET 101 TABLE 25 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, THROUGH 2020 ($ FIGURE 4 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, 2014-2020 ($ CANCER DRUGS: PAST PERFORMANCE 103 TABLE 26 GLOBAL SALES FOR ONCOLOGY DRUGS BY COMPANIES, 2012 AND 2013 ($ MILLIONS/%) EMERGING MARKETS 106 TABLE 27 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, THROUGH 2020 ($ FIGURE 5 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, 2014-2020 ($ 106 GASTRIC CANCER TREATMENT COSTS 109 Drugs Approved for Stomach (Gastric) Cancer 110 TABLE 28 GLOBAL MARKET FOR GASTRIC CANCER, THROUGH 2020 ($ 111 FIGURE 6 GLOBAL MARKET FOR GASTRIC CANCER, 2014-2020 ($ 111 TABLE 29 APPROVED DRUGS FOR GASTRIC CANCER TREATMENT 111 TABLE 30 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, THROUGH 2020 ($ FIGURE 7 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, 2014-2020 ($ TABLE 31 GLOBAL SALES FOR APPROVED BIOLOGICAL TREATMENT OF GASTRIC CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ FIGURE 8 GLOBAL SALES FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2013-2020 ($ TABLE 32 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF GASTRIC CANCER-MONOCLONAL ANTIBODIES, THROUGH 2020 ($ FIGURE 9 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2013-2020 ($ DRUGS IN DEVELOPMENT 114 MAJOR PLAYERS 114 Roche 114 TABLE 33 PATENT EXPIRIES 115 Merck/Bristol-Myers Squibb 115 ISSUES AND TRENDS AFFECTING MARKET 116 SUMMARY 117 98 98 99 99 102 102 105 106 112 112 113 113 114 114 CHAPTER 9 GASTRIC CANCER TREATMENT AND PREVENTION MARKET SIZE AND GROWTH 119
MARKET BY PRODUCT TYPE 121 CYRAMZA 121 Kadcyla (ado-trastuzumab emtansine) 122 Perjeta 122 Herceptin 123 ONCOLOGY MARKET AND GROWTH 123 Leading Drugs 123 TABLE 34 CANCER DRUGS SALES AND FORECAST, 2013-2016 ($ 123 MARKET BY GEOGRAPHICAL SEGMENTS 124 TABLE 35 ONCOLOGY TREATMENT, 2013 (BILLIONS) 124 ONCOLOGY PIPELINE 125 U.S. Market 125 JAPAN (ASIA) MARKET 126 TABLE 36 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ FIGURE 10 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER- MONOCLONAL ANTIBODIES, 2014-2020 ($ TABLE 37 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 ($ FIGURE 11 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 ($ EUROPE MARKET TABLE 38 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ FIGURE 12 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2014-2020 ($ TABLE 39 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 ($ ASIA MARKET 129 AUSTRALIA MARKET 129 SOUTH KOREA MARKET 129 CHINA MARKET 130 Gastric Cancer Market in China 130 TAIWAN MARKET 131 SINGAPORE MARKET 131 INDIA MARKET 132 BIOMAb-EGFR 133 TABLE 40 ASIA-PACIFIC COMPANIES IN ONCOLOGY 133 126 126 127 127 CHAPTER 10 PIPELINE, PATENTS AND NEW DEVELOPMENTS 135 RECENT DEVELOPMENTS AND APPROVALS 135 TABLE 41 APPROVED GASTRIC CANCER DRUGS, 2013-2014 136 NEW DRUGS/COMPANIES IN DEVELOPMENT 136 CLINICAL TRIALS IN ONCOLOGY 136 TABLE 42 ONCOLOGY CLINICAL TRIALS, 2009 136 FIGURE 13 ONCOLOGY CLINICAL TRIALS, 2009 136 Two New Clinical Trials for Advanced Gastric Cancer 137 TABLE 43 ROCHE - CLINICAL TRIALS 138 AZD4547 139
Pacific Edge 139 Oncolytics 140 CHAPTER 11 GLOBAL CANCER STATISTICS 142 CANCER TRENDS 142 TABLE 44 GLOBAL CANCER ESTIMATES, 2012 ( 142 TABLE 45 CANCER - NEW GLOBAL CASES DIAGNOSED, 2012 (EXCLUDING NON-MELANOMA SKIN CANCER) TABLE 46 COMMONLY DIAGNOSED CANCERS WORLDWIDE, 2012 ( 144 TABLE 47 AGE-STANDARDIZED RATE PER 100,000, 2012 145 TRENDS OVER TIME 146 FUTURE TRENDS 2020 147 TABLE 48 NUMBER OF NEW CANCER CASES BY SITE, 2020 (MILLIONS/%) 147 CANCER CURE AND COSTS 148 CAUSES OF RISE IN CANCER CASES 149 TABLE 49 AMERICAN CANCER SOCIETY RECOMMENDATIONS FOR CANCER PREVENTION PROJECTIONS TO 2030 150 TABLE 50 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 ( 150 FIGURE 14 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 ( 151 CURRENT CANCER TRENDS AND ECONOMIC BURDEN 152 The Burden of Cancer 152 EMERGING MARKETS 153 TABLE 51 GLOBAL INCIDENCE OF CANCER BY TYPE, 2012 ( 154 TABLE 52 GLOBAL MORTALITY OF CANCER BY TYPE, 2012 ( 154 CANCER PREVALENCE AND MARKET 155 GASTRIC CANCER 156 TABLE 53 ESTIMATED GASTRIC CANCERS BY REGION, 2012 (THOUSANDS) 157 TABLE 54 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF GASTRIC CANCER 158 AFRICA 158 ASIA 162 Cancer Prevention and Screening in Asia 163 CHINA AND JAPAN 166 Gastric H. pylori infection 169 Japan 169 China 170 MALAYSIA 170 INDIA 170 EUROPE 172 THE AMERICAS 173 TABLE 55 AMERICAS: CANCER FACTS 173 NORTH AMERICA 175 TABLE 56 UNITED STATES: LEADING NEW CANCER CASES, 2014 175 TABLE 57 UNITED STATES - LEADING NEW CANCER CASES, 2014 176 Canada 176 New Cases of Cancer in 2013 177 TABLE 58 PERCENT DISTRIBUTION OF ESTIMATED NEW STOMACH CANCER CASES, BY GENDER, IN CANADA, 2013 (%) 143 149 178
SUMMARY 178 CHAPTER 12 COMPANIES AND GLOBAL PLAYERS 180 COMPANIES 180 TABLE 59 GLOBAL PRESCRIPTION SALES FOR BIOLOGIC DRUGS, 2014 ($ 180 CANCER MARKET DYNAMICS 180 SELECTED COMPANIES AND PROFILES 181 BIOGEN IDEC 181 BRISTOL MYERS SQUIBB 181 ELI LILLY AND COMPANY 181 GLAXOSMITHKLINE 182 GENENTECH, INC 183 Hoffmann-LA Roche INC. 183 IMMUNOGEN 183 MERCK & COMPANY 186 NOVARTIS 187 PFIZER 189 ROCHE/GENENTECH 189 ONCOLYTICS 190 PACIFIC EDGE DIAGNOSTICS NZ 191 ZOVA BIOTHERAPEUTICS INC. 191 CHAPTER 13 PARTNERS IN DEVELOPMENT 193 RESEARCH AND DEVELOPMENT PARTNERSHIP AGREEMENTS AND TECHNOLOGY AND DIAGNOSTIC AGREEMENTS 193 CHAPTER 14 REFERENCES 195
LIST OF TABLES TABLE HEADING SUMMARY TABLE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND TREATMENT MARKET, THROUGH 2020 ($ TABLE 1 MAIN CATEGORIES OF CANCER 17 TABLE 2 TYPES OF STOMACH CANCER 29 TABLE 3 THE STAGES OF ADENOCARCINOMA STOMACH CANCER 29 TABLE 4 TESTS AND PROCEDURES USED TO DIAGNOSE STOMACH CANCER 30 TABLE 5 RISK FACTORS 32 TABLE 6 CAUSES OF GASTRIC CANCER 33 TABLE 7 SYMPTOMS 33 TABLE 8 DRUGS APPROVED FOR KIDNEY (RENAL CELL) CANCER 40 TABLE 9 GASTRIC SCREENING METHODS 54 TABLE 10 ESTIMATED INCIDENCE, MORTALITY AND PREVALENCE OF STOMACH CANCER WORLDWIDE, 2012 (THOUSANDS) TABLE 11 GLOBAL GASTRIC CANCER DIAGNOSTIC AND SCREENING MARKET, THROUGH 2020 ($ TABLE 12 TESTS AND PROCEDURES TO DETECT GASTRIC CANCER 64 TABLE 13 TESTS USED TO DETECT H. PYLORI 68 TABLE 14 GASTROINTESTINAL ENDOSCOPY EXAMINATIONS IN U.S., 2009 ( 68 TABLE 15 TYPES OF STANDARD TREATMENT 72 TABLE 16 APPROVED DRUGS FOR GASTRIC CANCER 76 TABLE 17 RECENT SURFACE ANTIGENS TARGETED BY MARKETED ANTIBODY THERAPEUTICS TABLE 18 MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER TREATMENT 88 TABLE 19 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER, 2014 ($ TABLE 20 GASTRIC CANCER AND ANTIBODIES IN DEVELOPMENT 91 TABLE 21 CANCER KEY FACTS 96 TABLE 22 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030 (MILLIONS OF PATIENTS) TABLE 23 GLOBAL CANCER RELATED ESTIMATED DEATHS BY REGION, 2012 AND 2030 ( TABLE 24 APPROVED ONCOLOGY DRUGS, 2013-2015 100 TABLE 25 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, THROUGH 2020 ($ TABLE 26 GLOBAL SALES FOR ONCOLOGY DRUGS BY COMPANIES, 2012 AND 2013 ($ MILLIONS/%) TABLE 27 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, THROUGH 2020 ($ TABLE 28 GLOBAL MARKET FOR GASTRIC CANCER, THROUGH 2020 ($ 111 TABLE 29 APPROVED DRUGS FOR GASTRIC CANCER TREATMENT 111 TABLE 30 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, THROUGH 2020 ($ TABLE 31 GLOBAL SALES FOR APPROVED BIOLOGICAL TREATMENT OF GASTRIC CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ TABLE 32 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF GASTRIC CANCER-MONOCLONAL ANTIBODIES, THROUGH 2020 ($ TABLE 33 PATENT EXPIRIES 115 TABLE 34 CANCER DRUGS SALES AND FORECAST, 2013-2016 ($ 123 TABLE 35 ONCOLOGY TREATMENT, 2013 (BILLIONS) 124 7 60 62 88 89 98 99 102 105 106 112 113 114
TABLE HEADING TABLE 36 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ TABLE 37 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 ($ TABLE 38 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, THROUGH 2020 ($ TABLE 39 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 ($ TABLE 40 ASIA-PACIFIC COMPANIES IN ONCOLOGY 133 TABLE 41 APPROVED GASTRIC CANCER DRUGS, 2013-2014 136 TABLE 42 ONCOLOGY CLINICAL TRIALS, 2009 136 TABLE 43 ROCHE - CLINICAL TRIALS 138 TABLE 44 GLOBAL CANCER ESTIMATES, 2012 ( 142 TABLE 45 CANCER - NEW GLOBAL CASES DIAGNOSED, 2012 (EXCLUDING NON-MELANOMA SKIN CANCER) TABLE 46 COMMONLY DIAGNOSED CANCERS WORLDWIDE, 2012 ( 144 TABLE 47 AGE-STANDARDIZED RATE PER 100,000, 2012 145 TABLE 48 NUMBER OF NEW CANCER CASES BY SITE, 2020 (MILLIONS/%) 147 TABLE 49 AMERICAN CANCER SOCIETY RECOMMENDATIONS FOR CANCER PREVENTION TABLE 50 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 ( 150 TABLE 51 GLOBAL INCIDENCE OF CANCER BY TYPE, 2012 ( 154 TABLE 52 GLOBAL MORTALITY OF CANCER BY TYPE, 2012 ( 154 TABLE 53 ESTIMATED GASTRIC CANCERS BY REGION, 2012 (THOUSANDS) 157 TABLE 54 TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF GASTRIC CANCER 158 TABLE 55 AMERICAS: CANCER FACTS 173 TABLE 56 UNITED STATES: LEADING NEW CANCER CASES, 2014 175 TABLE 57 UNITED STATES - LEADING NEW CANCER CASES, 2014 176 TABLE 58 PERCENT DISTRIBUTION OF ESTIMATED NEW STOMACH CANCER CASES, BY GENDER, IN CANADA, 2013 (%) TABLE 59 GLOBAL PRESCRIPTION SALES FOR BIOLOGIC DRUGS, 2014 ($ 180 126 127 143 149 178
LIST OF FIGURES FIGURE TITLE SUMMARY FIGURE GLOBAL GASTRIC CANCER DIAGNOSTIC/SCREENING AND TREATMENT MARKET, 2014-2020 ($ FIGURE 1 GLOBAL SALES FOR BEST-SELLING MONOCLONAL ANTIBODIES FOR GASTROINTESTINAL CANCER, 2014 ($ FIGURE 2 GLOBAL ESTIMATED INCIDENCE FOR CANCER BY REGION, 2009-2030 (MILLION PATIENTS) FIGURE 3 GLOBAL CANCER RELATED ESTIMATED DEATHS, BY REGION 2012 AND 2030 ( FIGURE 4 GLOBAL MARKET FOR ONCOLOGY DRUGS BY REGION, 2014-2020 ($ FIGURE 5 ASIA-PACIFIC MARKET FOR ONCOLOGY DRUGS, 2014-2020 ($ 106 FIGURE 6 GLOBAL MARKET FOR GASTRIC CANCER, 2014-2020 ($ 111 FIGURE 7 GLOBAL BIOTHERAPEUTICS SALES COMPARED TO TOTAL PRESCRIPTION DRUG SALES, 2014-2020 ($ FIGURE 8 GLOBAL SALES FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2013-2020 ($ FIGURE 9 GLOBAL SALES FOR POTENTIAL BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2013-2020 ($ FIGURE 10 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER- MONOCLONAL ANTIBODIES, 2014-2020 ($ FIGURE 11 JAPAN MARKET FOR BIOLOGICAL TREATMENT OF CANCER BY PRODUCT, 2008 AND 2009 ($ FIGURE 12 EUROPE MARKET FOR BIOLOGICAL TREATMENT OF CANCER - MONOCLONAL ANTIBODIES, 2014-2020 ($ FIGURE 13 ONCOLOGY CLINICAL TRIALS, 2009 136 FIGURE 14 GLOBAL CANCER INCIDENCE AND DEATHS, 2012 AND 2030 ( 151 7 89 98 99 102 112 113 114 126 127